Glycolysis-Enhancing α-1 Blockers and Parkinson Disease
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study states that the use of glycolysis-enhancing drugs, such as terazosin, doxazosin, and alfuzosin (drugs used for benign prostatic hyperplasia or unspecified urinary problems) may lower the risk of developing Parkinson's disease.

Parkinson's disease (PD) is a common neurodegenerative disease. The aim of this JAMA research was to determine whether the use of terazosin, doxazosin, and alfuzosin is associated with a decreased risk of developing PD.

This cohort study used active comparator control and propensity score-matched data. Men without PD who newly initiated terazosin/ doxazosin/ alfuzosin therapy or tamsulosin therapy, which is used for a similar indication but does not enhance glycolysis, and had at least 1 year of follow-up after medication start were included.

A cohort of 52365 propensity score-matched pairs of terazosin/doxazosin/alfuzosin and tamsulosin users were identified in the Danish registries and 94883 propensity score-matched pairs were identified in the Truven database.

--Patients in the Danish cohort who used terazosin/doxazosin/alfuzosin had a hazard ratio (HR) for developing PD of 0.88, and patients in the Truven cohort had an HR of 0.63.

--There was a dose-response association with short-duration, medium-duration, and long-duration use of terazosin/doxazosin/alfuzosin users having a decreasing HR in both the Danish cohort and Truven cohort.

In particular, the data suggest that users of terazosin/doxazosin/alfuzosin are at lower hazard of developing PD compared with users of tamsulosin.